1. Home
  2. FRES vs OGEN Comparison

FRES vs OGEN Comparison

Compare FRES & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FRES
  • OGEN
  • Stock Information
  • Founded
  • FRES 2010
  • OGEN 1996
  • Country
  • FRES United States
  • OGEN United States
  • Employees
  • FRES N/A
  • OGEN N/A
  • Industry
  • FRES Medical Specialities
  • OGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FRES Health Care
  • OGEN Health Care
  • Exchange
  • FRES Nasdaq
  • OGEN Nasdaq
  • Market Cap
  • FRES 70.9M
  • OGEN 9.8M
  • IPO Year
  • FRES 2020
  • OGEN N/A
  • Fundamental
  • Price
  • FRES $2.59
  • OGEN $1.13
  • Analyst Decision
  • FRES
  • OGEN
  • Analyst Count
  • FRES 0
  • OGEN 0
  • Target Price
  • FRES N/A
  • OGEN N/A
  • AVG Volume (30 Days)
  • FRES 10.6K
  • OGEN 133.4K
  • Earning Date
  • FRES 09-17-2024
  • OGEN 08-12-2024
  • Dividend Yield
  • FRES N/A
  • OGEN N/A
  • EPS Growth
  • FRES N/A
  • OGEN N/A
  • EPS
  • FRES N/A
  • OGEN N/A
  • Revenue
  • FRES $2,345,304.00
  • OGEN $20,629.00
  • Revenue This Year
  • FRES N/A
  • OGEN N/A
  • Revenue Next Year
  • FRES N/A
  • OGEN N/A
  • P/E Ratio
  • FRES N/A
  • OGEN N/A
  • Revenue Growth
  • FRES N/A
  • OGEN N/A
  • 52 Week Low
  • FRES $2.50
  • OGEN $0.97
  • 52 Week High
  • FRES $41.50
  • OGEN $7.74
  • Technical
  • Relative Strength Index (RSI)
  • FRES 34.96
  • OGEN 40.50
  • Support Level
  • FRES $2.56
  • OGEN $1.00
  • Resistance Level
  • FRES $3.40
  • OGEN $1.19
  • Average True Range (ATR)
  • FRES 0.37
  • OGEN 0.06
  • MACD
  • FRES -0.03
  • OGEN 0.03
  • Stochastic Oscillator
  • FRES 7.50
  • OGEN 57.41

About FRES Fresh2 Group Limited

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Share on Social Networks: